Windlas Biotech Limited Sustainability Profile
Windlas Biotech Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 2001, the company has established itself as a leader in the development and manufacturing of high-quality generic formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. With a strong focus on innovation, Windlas Biotech offers a diverse portfolio of products that cater to multiple therapeutic segments, including cardiovascular, anti-diabetic, and anti-infective medications. The company is recognised for its state-of-the-art manufacturing facilities, which adhere to stringent international quality standards. Windlas Biotech has achieved significant milestones, including regulatory approvals from global health authorities, positioning itself as a trusted partner in the pharmaceutical supply chain. Its commitment to quality and sustainability has solidified its reputation in the competitive biotech landscape.
DitchCarbon Score
How does Windlas Biotech Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Windlas Biotech Limited's score of 16 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Windlas Biotech Limited's reported carbon emissions
Windlas Biotech Limited, headquartered in India, currently does not have any publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives related to climate commitments. The absence of emissions data suggests that the company may not have established a formal framework for tracking its carbon footprint or may be in the early stages of developing such initiatives. As of now, Windlas Biotech Limited has not cascaded any emissions data from a parent or related organization, indicating that it operates independently in terms of climate reporting. The company has not set any Science-Based Targets Initiative (SBTi) reduction targets or made any climate pledges that are publicly documented. In the context of the pharmaceutical industry, where sustainability and climate action are increasingly important, Windlas Biotech Limited may need to consider establishing measurable climate commitments and reporting frameworks to align with industry standards and stakeholder expectations.
How Carbon Intensive is Windlas Biotech Limited's Industry?
How Carbon Intensive is Windlas Biotech Limited's Location?
Windlas Biotech Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Windlas Biotech Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
